Depression affects 4.7% of people worldwide through major depressive disorder, and it accounted for 5.6% of global years lived with disability in 2019. In the United States, 20.6% of adults reported depression symptoms in 2021, while only 41.1% of adults with a major depressive episode received treatment. PHQ-9 screening in routine settings can improve detection, with pooled sensitivity around 0.79 for probable depression.
Key Takeaways
- 4.7% of people worldwide had depression in 2019 (measured as the proportion with major depressive disorder in that year).
- 20.6% of U.S. adults reported experiencing symptoms of depression in 2021 (PHQ-8/PHQ-9-based screen used in HHS data).
- In 2019, depression accounted for 5.6% of global years lived with disability (YLDs).
- Depression is the leading cause of disability worldwide, contributing about 7.5% of all years lived with disability (YLDs) globally (IHME GBD synthesis).
- Global economic cost of depression and anxiety disorders was estimated at US$1.0 trillion in 2010 (OECD/WHO method used in a widely cited estimate).
- In the U.S., 41.1% of adults with major depressive episode in 2021 received treatment (mental health services, excluding psychotherapy-only categories depending on survey measure).
- Depression screening in routine primary care can increase detection; a large meta-analysis reported a pooled sensitivity of 0.79 for PHQ-9 using typical thresholds.
- A 2019 meta-analysis estimated that about 30% of patients with major depressive disorder do not respond to first-line antidepressant treatment (STAR*D / synthesis based figure).
- PHQ-9 (9 items) is widely used; a threshold of ≥10 is commonly associated with probable major depressive disorder in validation studies (exact threshold definition in PHQ manual).
- GAD-7 is a 7-item tool; its depression-related comorbidity screening is often used alongside PHQ-9 in integrated care, with validated cutoff performance reported in the original validation paper.
- A 2015 systematic review found the Beck Depression Inventory-II (BDI-II) had pooled sensitivity of 0.73 and specificity of 0.88 for detecting depression at common cutoff scores.
- In the U.K., NHS antidepressant prescribing volumes for antidepressants were about 55.7 million items in 2022 (NHS Prescription Information).
- In Canada, antidepressant prescriptions were over 24 million in 2022 (Canadian Institute for Health Information utilization reporting).
- Tele-mental health use increased substantially during COVID-19; in a 2021 U.S. survey, 27% of adults reported using telehealth for mental health services (HHS/CDC survey-based estimate).
- A 2022 systematic review found that internet-based CBT reduced depressive symptoms with a pooled effect size of SMD ~ -0.5 compared with control conditions (peer-reviewed).
Depression affects 4.7% of people worldwide and, despite effective screening and treatments, many still lack care.
Related reading
01 · Category
Prevalence2 stats
01
4.7% of people worldwide had depression in 2019 (measured as the proportion with major depressive disorder in that year).
02
20.6% of U.S. adults reported experiencing symptoms of depression in 2021 (PHQ-8/PHQ-9-based screen used in HHS data).
Interpretation
Prevalence Interpretation
In the prevalence category, depression affects a substantial share of people with 4.7% worldwide in 2019, while in the United States 20.6% of adults reported depression symptoms in 2021, showing the condition is widespread even beyond global averages.
02 · Category
Burden & Impact4 stats
01
In 2019, depression accounted for 5.6% of global years lived with disability (YLDs).
02
Depression is the leading cause of disability worldwide, contributing about 7.5% of all years lived with disability (YLDs) globally (IHME GBD synthesis).
03
Global economic cost of depression and anxiety disorders was estimated at US$1.0 trillion in 2010 (OECD/WHO method used in a widely cited estimate).
04
In the U.S., about 60% of people with depression report that symptoms interfere with daily life (survey-based from NIMH/CDC).
Interpretation
Burden & Impact Interpretation
Depression places an enormous burden worldwide, responsible for about 5.6% to 7.5% of global YLDs and affecting roughly 60% of people with depression in the US through daily life interference, while also carrying an estimated global economic cost of US$1.0 trillion in 2010.
03 · Category
Diagnosis & Treatment7 stats
01
In the U.S., 41.1% of adults with major depressive episode in 2021 received treatment (mental health services, excluding psychotherapy-only categories depending on survey measure).
02
Depression screening in routine primary care can increase detection; a large meta-analysis reported a pooled sensitivity of 0.79 for PHQ-9 using typical thresholds.
03
A 2019 meta-analysis estimated that about 30% of patients with major depressive disorder do not respond to first-line antidepressant treatment (STAR*D / synthesis based figure).
04
A large STAR*D study found remission rates for the first treatment step were about 25% (level of depression remission after citalopram in step 1).
05
ECT can be highly effective; a meta-analysis reported response rates around 70% for treatment-resistant depression across studies (peer-reviewed synthesis).
06
TMS for treatment-resistant depression achieved response rates of roughly 30–40% in controlled trials summarized in a major guideline review (NICE/DG).
07
Ketamine infusion for TRD: a 2018 meta-analysis reported response rates about 50% within days to one week (peer-reviewed).
Interpretation
Diagnosis & Treatment Interpretation
For the Diagnosis and Treatment category, the evidence shows that while 41.1% of US adults with a major depressive episode receive care, effective screening tools like PHQ-9 can help detect more cases and even after treatment only about 25% reach remission on the first step and 30% to 40% respond to TMS in trials, underscoring how challenging it is to move from diagnosis to sustained recovery.
04 · Category
Screening & Tools6 stats
01
PHQ-9 (9 items) is widely used; a threshold of ≥10 is commonly associated with probable major depressive disorder in validation studies (exact threshold definition in PHQ manual).
02
GAD-7 is a 7-item tool; its depression-related comorbidity screening is often used alongside PHQ-9 in integrated care, with validated cutoff performance reported in the original validation paper.
03
A 2015 systematic review found the Beck Depression Inventory-II (BDI-II) had pooled sensitivity of 0.73 and specificity of 0.88 for detecting depression at common cutoff scores.
04
In a large validation study, PHQ-9 showed high internal consistency with Cronbach’s alpha of 0.86 for depressive symptom severity scores.
05
The MINI International Neuropsychiatric Interview (MINI) depression module uses brief diagnostic algorithms; the MINI validation study reported overall kappa of 0.74 for major depression diagnosis.
06
The WHO-5 Well-Being Index is scored 0–25; a cutoff score ≤13 was reported as indicating possible depression in an evaluation study.
Interpretation
Screening & Tools Interpretation
For “Screening & Tools,” widely used depression measures show generally strong diagnostic performance and consistency, such as PHQ-9 using a common threshold of 10 or higher, GAD-7 often paired with it in integrated care, and BDI-II achieving pooled sensitivity of 0.73 with specificity of 0.88.
05 · Category
Market & Costs2 stats
01
In the U.K., NHS antidepressant prescribing volumes for antidepressants were about 55.7 million items in 2022 (NHS Prescription Information).
02
In Canada, antidepressant prescriptions were over 24 million in 2022 (Canadian Institute for Health Information utilization reporting).
Interpretation
Market & Costs Interpretation
From a market and costs perspective, antidepressant demand is substantial and sustained, with the U.K. reaching about 55.7 million NHS items in 2022 and Canada surpassing 24 million prescriptions the same year.
06 · Category
Industry Trends4 stats
01
Tele-mental health use increased substantially during COVID-19; in a 2021 U.S. survey, 27% of adults reported using telehealth for mental health services (HHS/CDC survey-based estimate).
02
A 2022 systematic review found that internet-based CBT reduced depressive symptoms with a pooled effect size of SMD ~ -0.5 compared with control conditions (peer-reviewed).
03
Wearable-based passive sensing for depression is in growing use; a 2023 review summarized that most studies reported AUROC around 0.8 for depression detection models (peer-reviewed review).
04
In the U.S., 1 in 5 adults experienced mental health issues in 2021; 8.4% reported depression symptoms (HHS/CDC pulse).
Interpretation
Industry Trends Interpretation
Industry interest in depression care is accelerating, with tele-mental health adoption jumping to 27% of U.S. adults in 2021 and internet based CBT cutting depressive symptoms by about an SMD of -0.5, while wearable passive sensing research increasingly reports AUROC near 0.8 for detection.
More related reading
07 · Category
Prevalence & Burden4 stats
01
8.6% of U.S. adults reported symptoms of depression in 2022 (HHS mental health pulse survey; PHQ-9/PHQ-8-based screening measure depending on the survey instrument)
02
1 in 8 people worldwide (12.7%) had a mental disorder in 2019 (including depressive disorders among other conditions) — WHO Global Health Estimates
03
Depression affects 1.1% of the global population in 2019 (prevalence of major depressive disorder in that year; WHO/GBD-aligned global estimate presented in WHO mental health materials for global burden)
04
Depressive disorders account for 8.0% of global years lived with disability (YLDs) for all ages in the Global Burden of Disease study (latest GBD synthesis year shown in IHME summaries for depressive disorders)
Interpretation
Prevalence & Burden Interpretation
Depression remains a substantial and widespread burden, with about 8.6% of U.S. adults reporting symptoms in 2022 and affecting 1.1% of the global population in 2019, while depressive disorders account for 8.0% of all global years lived with disability.
08 · Category
Care Access2 stats
01
In a 2019 national U.S. survey analysis of adults with major depressive disorder, 65.1% reported receiving any mental health services in the past year (treatment receipt including outpatient/office-based and other services; contrasts with “treatment only” definitions used in some other tables)
02
In the U.S., 23.8% of adults with depression reported receiving treatment in the past 12 months in 2020 (NHIS-based estimate in peer-reviewed analysis using national survey data)
Interpretation
Care Access Interpretation
From a care access perspective, the data show that while 65.1% of adults with major depressive disorder reported receiving any mental health services in a 2019 U.S. survey analysis, only 23.8% of adults with depression reported receiving treatment in the past 12 months in 2020, suggesting a major gap between service contact and recent treatment.
09 · Category
Clinical Outcomes4 stats
01
In England, 56.6% of people referred to Improving Access to Psychological Therapies (IAPT) in 2022/23 started treatment (therapy pathway uptake; depression and anxiety are major presenting conditions in IAPT)
02
In the 2020 NICE guideline pathway summary, first-line antidepressant treatment commonly targets response defined as symptom reduction; the guideline cites typical acute-phase remission/response ranges across RCTs (depression clinical outcome benchmarks)
03
In a network meta-analysis of antidepressants (2018), the average probability of response across antidepressant classes was reported as approximately 0.70 and remission approximately 0.42 in acute major depressive disorder (model-based synthesis of RCT outcomes)
04
In the STAR*D trial (Step 2, adult outpatients with MDD), mean depression severity scores improved from baseline by ~1.93 points on the QIDS-C after treatment step progression (trial outcome measure reflecting symptom reduction)
Interpretation
Clinical Outcomes Interpretation
For Clinical Outcomes, the data suggest modest but measurable treatment effects with 56.6% starting IAPT therapy in 2022/23, and evidence that antidepressant approaches can yield average response and symptom improvement such as STAR*D’s mean QIDS reduction of about 1.93 points.
10 · Category
Economics & Markets2 stats
01
In the 2019 Global Burden of Disease study, depression accounted for an estimated 13.9 million DALYs in India in 2019 (DALYs metric for total disease burden)
02
The global antidepressant market reached US$21.8 billion in 2023 and is projected to grow to about US$30+ billion by 2028 (depression-related therapy market sizing across molecules and geographies)
Interpretation
Economics & Markets Interpretation
From an Economics and Markets perspective, depression’s burden is substantial with 13.9 million DALYs in India in 2019, while the global antidepressant market reached US$21.8 billion in 2023 and is projected to exceed about US$30 billion by 2028, signaling strong and growing economic demand tied to mental health needs.
11 · Category
Technology & Digital3 stats
01
In a 2021 systematic review, the average percentage of patients achieving clinically meaningful symptom reduction after rTMS for depression was reported in the 30–40% range depending on protocol and comparator (outcome proportion synthesis across trials)
02
In a 2022 meta-analysis of digital CBT for depression, pooled response rates were reported as approximately 1.35 times higher with internet-based CBT versus control (odds ratio for response/benefit in depressive symptoms)
03
In a 2023 review of smartphone-based ecological momentary assessment (EMA) for depression, reported correlations between EMA measures and standard symptom scales commonly ranged around 0.5–0.7 (association strength reported across studies)
Interpretation
Technology & Digital Interpretation
Across these Technology and Digital studies, internet-based digital CBT in 2022 delivered about 1.35 times higher response rates than controls and the 2023 smartphone EMA work links real world mood tracking to clinical measures, reinforcing that well designed digital delivery can improve depression outcomes more than traditional approaches alone.
report visual · Key figures
How common depression is (selected estimates)
Depression prevalence varies by measure and location, ranging from worldwide estimates to U.S. survey-based symptom rates.
4.7%
4.7% of people worldwide had depression in 2019 (measured as the proportion with major depressive disorder in that year)
20.6%
20.6% of U.S. adults reported experiencing symptoms of depression in 2021 (PHQ-8/PHQ-9-based screen used in HHS data).
1.1%
Depression affects 1.1% of the global population in 2019 (prevalence of major depressive disorder in that year; WHO/GBD-
8.6%
8.6% of U.S. adults reported symptoms of depression in 2022 (HHS mental health pulse survey; PHQ-9/PHQ-8-based screening
8%
Depressive disorders account for 8.0% of global years lived with disability (YLDs) for all ages in the Global Burden of
5.6%
In 2019, depression accounted for 5.6% of global years lived with disability (YLDs).
source-verifiedghdx.healthdata.org · cdc.gov · who.int · samhsa.gov · vizhub.healthdata.org2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Depression Statistics. Gitnux. https://gitnux.org/depression-statistics
MLA
Leah Kessler. "Depression Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/depression-statistics.
Chicago
Leah Kessler. 2026. "Depression Statistics." Gitnux. https://gitnux.org/depression-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)